AZD3965 - CAS 1448671-31-5
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit MCT4 at 10 μM. Both lactate transport and cell growth are potently inhibited by AZD3965 in lymphoma cell lines that preferentially express MCT1. Lactate transport inhibition in some cell lines also induces a cytotoxic effect. In vitro combination studies show that lactate transport inhibition can enhance the induction of cell death by doxorubicin. Blocking lactate transport in vitro also leads to a rapid inhibition of glucose uptake in the Raji Burkitt's lymphoma cell line. In vivo, AZD3965 is well tolerated and induces a dose and time dependent accumulation of lactate in the tumours, suppresses tumour growth and in the Raji model potentiates the effects of Rituxan, doxorubicin and bendamustine.The selective inhibition of lactate transport by the MCT1 inhibitor AZD3965 offers an novel mechanism for targeting the metabolic phenotype in tumours that preferentially express MCT1.
Publictions citing BOC Sciences Products
  • >> More
Related CAS:
White to off-white solid powder
(S)-5-(4-hydroxy-4-methylisoxazolidine-2-carbonyl)-1-isopropyl-3-methyl-6-((3-methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione; AZD3965; AZD-3965; AZD 3965
Canonical SMILES:
1.Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport.
Bola BM1, Chadwick AL2, Michopoulos F3, Blount KG4, Telfer BA4, Williams KJ4, Smith PD3, Critchlow SE3, Stratford IJ5. Mol Cancer Ther. 2014 Dec;13(12):2805-16. doi: 10.1158/1535-7163.MCT-13-1091. Epub 2014 Oct 3.
Inhibition of the monocarboxylate transporter MCT1 by AZD3965 results in an increase in glycolysis in human tumor cell lines and xenografts. This is indicated by changes in the levels of specific glycolytic metabolites and in changes in glycolytic enzyme kinetics. These drug-induced metabolic changes translate into an inhibition of tumor growth in vivo. Thus, we combined AZD3965 with fractionated radiation to treat small cell lung cancer (SCLC) xenografts and showed that the combination provided a significantly greater therapeutic effect than the use of either modality alone. These results strongly support the notion of combining MCT1 inhibition with radiotherapy in the treatment of SCLC and other solid tumors.
2.Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer.
Polański R1, Hodgkinson CL, Fusi A, Nonaka D, Priest L, Kelly P, Trapani F, Bishop PW, White A, Critchlow SE, Smith PD, Blackhall F, Dive C, Morrow CJ. Clin Cancer Res. 2014 Feb 15;20(4):926-37. doi: 10.1158/1078-0432.CCR-13-2270. Epub 2013 Nov 25.
PURPOSE: The monocarboxylate transporter 1 (MCT1) inhibitor, AZD3965, is undergoing phase I evaluation in the United Kingdom. AZD3965 is proposed, via lactate transport modulation, to kill tumor cells reliant on glycolysis. We investigated the therapeutic potential of AZD3965 in small cell lung cancer (SCLC) seeking rationale for clinical testing in this disease and putative predictive biomarkers for trial use.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related MCT Products

CAS 496791-37-8 AR-C155858

(CAS: 496791-37-8)

AR-C155858 is a novel inhibitor of the monocarboxylate transporters (MCTs) MCT1 and MCT2, but exhibits no activity at MCT4. It can be used to probe MCTs’ roles ...

CAS 1472624-85-3 7ACC2

(CAS: 1472624-85-3)

7ACC2 did not influence the prothrombin time which, together with a good in vitro ADME profile, supports the potential of this new family of compounds to act as...

CAS 50995-74-9 7ACC1

(CAS: 50995-74-9)

7ACC1 selectively interferes with lactate fluxes in the lactate-rich tumor microenvironment and inhibits lactate influx but not efflux in tumor cells expressing...

(CAS: 216685-07-3)

AR-C117977 is a potent MCT1 inhibitor that inhibited the rat MLR and was more potent than cyclosporin A (CsA). AR-C117977 can reduce vimmune responses both in v...

CAS 1448671-31-5 AZD3965

(CAS: 1448671-31-5)

AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit M...

CAS 56396-35-1 UK-5099

(CAS: 56396-35-1)

UK-5099 is a potent inhibitor of plasma membrane monocarboxylate transporters (MCTs) and the mitochondrial pyruvate carrier (MPC). It inhibits pyruvate-dependen...

Chemical Structure

CAS 1448671-31-5 AZD3965

Quick Inquiry

Verification code

Featured Items